Uncategorized

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives

Pharmaceutical patent strategy is often discussed like a binary choice: fight, settle, or walk away.
But the real world is messier—and more expensive.
In a recent DrugPatentWatch piece, the “cut / keep / cash” decision matrix reframes patent portfolios…

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives Read Post »

Uncategorized

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out

The most valuable window in pharma isn’t after launch—it’s before the patent clock runs out.
In commercial market access, timing is destiny. But most business development teams still behave like they’re selling after the product story is already writte…

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out Read Post »

Biotechblog
Scroll to Top